Compare Moderna, Inc. (MRNA) vs NetEase Inc (NTES) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs NetEase Inc — how do they compare? Moderna, Inc. trades at $224.78 (market cap $78.65B), while NetEase Inc trades at $124.27 (market cap $76.09B). The key difference: Moderna, Inc. and NetEase Inc are close in size by market cap, and NetEase Inc pays a 2.45% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and NetEase Inc for 73 Days on average.
| MRNA | NTES | |
|---|---|---|
Market Cap | $78.65B | $76.09B |
Volume | 37,373,437 | 486,447 |
Sector | Health | Technology |
52-Week High | $203.46 | $152.85 |
52-Week Low | $22.36 | $109.26 |
Typical Hold Time | 59 Days | 73 Days |
Enterprise Value | $74.80B | $51.81B |
Dividend Yield | — | 2.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $225.00, up 14.52% in 24 hours, approaching its 52-week high. The stock shows strong technical momentum with bullish moving averages and support at $194. Fundamentally, while revenue has declined from pandemic peaks to $1.92B in 2025, the company continues to beat EPS expectations and maintains a robust pipeline in oncology and respiratory vaccines. Recent inclusion in the Nasdaq-100 index has generated positive momentum, though valuation metrics remain elevated with a P/S ratio of 35.08.
Outlook remains bifurcated - significant growth potential exists in the cancer vaccine pipeline and respiratory vaccine expansion, but current valuations appear stretched relative to financial performance. Key risks include execution challenges in new therapeutic areas, competitive pressure from Pfizer/BioNTech, and dependence on pipeline success beyond COVID-19 vaccines. Analyst consensus shows cautious optimism with a $115.70 price target despite recent downgrades.
NTES trades at $124.20, up 2.98% today, with a neutral technical signal and mixed earnings history. The company reported Q2 2026 revenue growth of 8% year-over-year to $4.4 billion, though EPS missed expectations. Strong fundamentals include a 27.88% net income margin and robust cash flow from operations of $50.74 billion in 2025. Recent news highlights focus on gaming performance and AI investments.
Outlook remains positive with an 81.82% analyst buy rating and a $168.00 consensus price target, implying significant upside. Risks include earnings volatility and competitive pressures in the gaming sector. The stock presents a value opportunity given its reasonable P/E of 15.92 and strong balance sheet with $137.58 billion in cash.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About NetEase Inc
NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).
Read more on NTES →
